![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
| Sustancia en estudio para el tratamiento del cáncer de hígado. Se elabora al unir una sustancia radiactiva llamada indio 111 a un anticuerpo monoclonal llamado HuAFP31. El HuAFP31 se une a las células tumorales que producen alfaproteína (AFP) y el indio (In 111) puede destruir las células tumorales. Es un tipo de radioinmunoconjugado. |
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081101152903im_/http://www.nci.nih.gov/images/spacer.gif) |